COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management

Yasar Sattar, Icahn School of Medicine at Mount Sinai
Waqas Ullah, Internal Medicine
Hiba Rauf, American Society of Clinical Oncology
Hafeez ul Hassan Virk, University Hospitals Case Medical Center
Sunita Yadav, Jacobi Medical Center
Medhat Chowdhury, Rochester General Hospital
Michael Connerney, Icahn School of Medicine at Mount Sinai
Sahil Mamtani, Jacobi Medical Center
Mohit Pahuja, Rochester General Hospital
Raj D. Patel, Wayne State University
Tanveer Mir, Wayne State University
Talal Almas, Wayne State University
Homam Moussa Pacha, University of Texas Health Science Center at Houston
M. Chadi Alraies, Wayne State University

Abstract

Coronavirus Disease 2019 (COVID-19) is a rapidly progressing global pandemic that may present with a variety of cardiac manifestations including, but not limited to, myocardial injury, myocardial infarction, arrhythmias, heart failure, cardiomyopathy, shock, thromboembolism, and cardiac arrest. These cardiovascular effects are worse in patients who have pre-existing cardiac conditions such as coronary artery disease, hypertension, diabetes mellitus, and coagulation abnormalities. Other predisposing risk factors include advanced age, immunocompromised state, and underlying systemic inflammatory conditions. Here we review the cellular pathophysiology, clinical manifestations and treatment modalities of the cardiac manifestations seen in patients with COVID-19.